Most Read

The halted trails also include the large-scale, pivotal and multi-country phase 3 ENSEMBLE trial of the company’s Covid-19 vaccine candidate called JNJ-78436735, which is being developed by Janssen

The phase 3 PENELOPE-B trial has failed to achieve the primary endpoint of improved invasive disease-free survival (iDFS) in women with hormone receptor-positive (HR+), human epidermal growth factor-negative

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), along with Inova Health System, has sponsored the trial. Fostamatinib, which is sold

The deal also includes an option that allows supply of up to 200 million additional doses to the EU member states. This agreement was signed after the conclusion

With the IND approval in place, the company expects to launch a phase 2b/3 sequential clinical trial of AB201 in the fourth quarter of 2020. The phase 2b

The companies announced the global expansion to phase 3 of the Covid-19 monoclonal antibody efficacy trial – intent to care early (COMET-ICE) to assess VIR-7831 for the early

Under the deal, Scribe Therapeutics and Biogen will develop and commercialise CRISPR-based therapies to treat amyotrophic lateral sclerosis (ALS). X-Editing (XE), which is Scribe’s first technology, is said

MyoKardia is engaged in the discovery and development of targeted therapies to treat serious cardiovascular diseases. As per terms of the merger deal, BMS subsidiary will begin a

FDA has provided the breakthrough therapy status based on data from the BPDCN cohort of the first-in-human study of IMGN632, said ImmunoGen. IMGN632 is a CD123-targeting ADC, which